Key Highlights
- Kodiak plans to file for approval of Zenkuda across multiple indications in the fourth quarter of 2026.
- Health care was one of only three S&P 500 sectors to rise, and several small drug developers posted big gains.
- Kodiak's move, which lifted its Market Value to about $5.7 billion, was in a league of its own.
- The macro backdrop mattered as well, with futures pricing a majority chance of another Fed hike in October.
Kodiak Sciences (NASDAQ:KOD) more than doubled on Monday, September 28 after two experimental eye drugs hit their goals in a pivotal Phase 3 trial, turning a small biotech into the day's biggest story on a down day for Wall Street.
The move
Kodiak Sciences exploded higher on Monday, September 28, closing at $90.16. Market reports put the company's market value at about $5.7 billion after the move.
It was, by a wide margin, the most dramatic gain among notable names on a day when the S&P 500 fell 59.72 points to 7,683.69 and the Nasdaq Composite dropped 248.34 points to 26,820.38.
The data behind the rally
The catalyst was Kodiak's pivotal Phase 3 DAYBREAK trial in wet age-related macular degeneration, a leading cause of vision loss in older adults. Both of its experimental drugs, Zenkuda and tabirafusp-ted, met the primary goal of showing vision gains that were not inferior to aflibercept, an established treatment. "Both drugs achieved vision gains at one year that were not inferior to aflibercept," market reports reported.
The excitement centers on dosing. According to the company, more than half of Zenkuda patients were on six-month dosing at the end of year one, with no cases of eye inflammation reported. Patients with wet AMD (NASDAQ:AMD) often need frequent eye injections, so a treatment that can be given less often could be a major advantage.
What management said
"The strength of these DAYBREAK data positions us for the next stage of Kodiak's evolution, as we prepare for the planned commercialization of Zenkuda," chief executive Victor Perlroth said in the company's release. Chief medical officer J. Pablo Velazquez-Martin said, "DAYBREAK demonstrated the attributes we designed Zenkuda to achieve: rapid disease control in wet AMD and the potential for six-month durability."
Kodiak plans to file for approval of Zenkuda across multiple indications in the fourth quarter of 2026.
Why it dominated the conversation
The story had every ingredient that draws traders' attention: a clear binary event, a huge move and a relatable disease. It also stood in sharp contrast to the rest of the market. The 10-year Treasury Yield hit its highest level since 2007, chip stocks slid on reports that OpenAI paused Training of some frontier models, and Boeing (NYSE:BA) hit its lowest level of 2026 after an FAA delay.
Kodiak's rally came on a strong day for biotech more broadly. Health care was one of only three S&P 500 sectors to rise, and several small drug developers posted big gains.
Kodiak was not the only biotech in the spotlight. Lifecore Biomedical (NASDAQ:LFCR) soared after agreeing to be acquired by Webster Equity Partners, and Accuray (NASDAQ:ARAY) surged on a Partnership with Samsung NeuroLogica. But Kodiak's move, which lifted its market value to about $5.7 billion, was in a league of its own.
The regulatory filing is the next milestone
The next milestone is the regulatory filing planned for the fourth quarter, followed by the review process. Investors will also watch for full data presentations, commercial plans and how the company funds a launch.
Moves this large often bring heavy Volatility in the following sessions as traders take profits or pile in. The macro backdrop matters as well: futures price a majority chance of another Federal Reserve hike in October, with PCE Inflation due Wednesday and the September jobs report Friday. For Kodiak, though, the company-specific story is likely to keep driving the stock.
_11_16_2026_14_38_45_453029.jpg)





Please wait processing your request...